Effect of biological DMARDs and JAK inhibitors in pain of chronic inflammatory arthritis

References

• Ramiro S, Radner H, Van Der Heijde DM, et al. Combination therapy for pain management in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012;90(SUPPL.90):47–55.
   PubMedGoogle Scholar
• Mars NJ, Kerola AM, Kauppi MJ, et al. Patients with rheumatic diseases share similar patterns of healthcare resource utilization. Scand J Rheumatol. 2019;48(4):300–307.
   PubMed Web of Science ®Google Scholar
• Chen SJ, Lin GJ, Chen JW, et al. Immunopathogenic mechanisms and novel immune-modulated therapies in rheumatoid arthritis. Int J Mol Sci. 2019;20:6.
   Web of Science ®Google Scholar
• Salaffi F, Giacobazzi G, Di CM. Pain and the JAK-STAT pathway. Pain Res Manag. 2018;2018:15.
   Web of Science ®Google Scholar
• Busch-Dienstfertig M, González-Rodríguez S. IL-4, JAK-STAT signaling, and pain. JAKSTAT. 2013;2(4):e27638.
   PubMedGoogle Scholar
• Baral P, Udit S, Chiu IM. Pain and immunity: implications for host defence. Nat Rev Immunol. 2019;19(7):433.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Nucera V, Masala IF, et al. Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. Pharmacol Res. 2019;149(June):104402.
   PubMedGoogle Scholar
• Witter JP. The promise of patient-reported outcomes measurement information system-turning theory into reality. A uniform approach to patient-reported outcomes across rheumatic diseases. Rheum Dis Clin North Am. 2016;42(2):377–394.
   PubMed Web of Science ®Google Scholar
• Liu JA, Yu J, Cheung CW. Immune actions on the peripheral nervous system in pain. Int J Mol Sci. 2021;22(3):1–18.
   Web of Science ®Google Scholar
• Tzeng HT, Chyuan IT, Lai JH. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: a focus on molecular mechanisms and therapeutic potential. Biochem Pharmacol. 2021;193(September):114760.
   PubMedGoogle Scholar
• Kilic G, Kilic E, Nas K, et al. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required? Rheumatol Int. 2019;39(1):73–81.
   PubMed Web of Science ®Google Scholar
• Khan NA, Spencer HJ, Abda E, et al. Determinants of discordance in patients’ and physicians’ rating of rheumatoid arthritis disease activity. Arthritis Care Res. 2012 Feb;64(2):206–214.
   PubMed Web of Science ®Google Scholar
• Purabdollah M, Lakdizaji S, Rahmani A. Relationship between sleep, pain and inflammatory markers in patients with rheumatoid arthritis. J Caring Sci. 2017;6(3):249–255.
   PubMedGoogle Scholar
• McWilliams DF, Walsh DA. Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. BMC Musculoskelet Disord. 2016;17(1):337.
   PubMedGoogle Scholar
• Raja SN, Carr DB, Cohen M, et al. The revised international association for the study of pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161(9):1976–1982.
   PubMed Web of Science ®Google Scholar
• Trouvin AP, Perrot S. New concepts of pain. Best Pract Res Clin Rheumatol. 2019;33(3):101415.
   PubMed Web of Science ®Google Scholar
• Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–1635.
   PubMed Web of Science ®Google Scholar
• Merskey H. Logic, truth and language in concepts of pain. Qual Life Res. 1994;3(1 Supplement):S69–S76.
   PubMedGoogle Scholar
• Kosek E, Clauw D, Nijs J, et al. Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. Pain. 2021;162(11):2629–2634.
   PubMed Web of Science ®Google Scholar
• Fitzcharles MA, Cohen SP, Clauw DJ, et al. Nociplastic pain: towards an understanding of prevalent pain conditions. Lancet. 2021;397(10289):2098–2110.
   PubMed Web of Science ®Google Scholar
• Bailly F, Cantagrel A, Bertin P, et al. Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic. RMD Open. 2020;6(2):1–6.
   Web of Science ®Google Scholar
• Fillingim RB, Loeser JD, Baron R, et al. Assessment of chronic pain: domains, methods, and mechanisms. J Pain. 2016;17(9 Suppl):T10–20.
   PubMed Web of Science ®Google Scholar
• Van Tuyl LHD, Sadlonova M, Hewlett S, et al. The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Ann Rheum Dis. 2017;76(5):855–861.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Sarzi-Puttini P, Atzeni F. How to measure chronic pain: new concepts. Best Pract Res Clin Rheumatol. 2015;29(1):164–186.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Stancati A, Silvestri CA, et al. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain. 2004;8(4):283–291.
   PubMed Web of Science ®Google Scholar
• Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183–196.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Olofsson T, Wallman JK, Jöud A, et al. Pain over two years after start of biologic versus conventional combination treatment in early rheumatoid arthritis: results from a Swedish randomized controlled trial. Arthritis Care Res. 2021;73(9):1312–1321.
   Web of Science ®Google Scholar
• Van De Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of Adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516.
   PubMed Web of Science ®Google Scholar
• Strand V, Rentz AM, Cifaldi MA, et al. Health-related quality of life outcomes of Adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol. 2012;39(1):63–72.
   PubMed Web of Science ®Google Scholar
• Keystone EC, Schiff MH, Kremer JM, et al. Once-Weekly Administration of 50 mg Etanercept in Patients with Active Rheumatoid Arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(2):353–363.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253–259.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Vencovsky J, Van Vollenhoven RF, et al. Extended report: efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68(6):805.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–221.
   PubMed Web of Science ®Google Scholar
• Harrold LR, John A, Reed GW, et al. Impact of tocilizumab monotherapy on clinical and patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. Rheumatol Ther. 2017;4(2):405–417.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70(5):755–759.
   PubMed Web of Science ®Google Scholar
• Jansen JP, Buckley F, Dejonckheere F, et al. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs–a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12(1):1.
   PubMedGoogle Scholar
• Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18(1):1.
   PubMedGoogle Scholar
• Burmester GR, Bikerk VP, Buch MH, et al. Sarilumab monotherapy versus sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis. Rheumatol. 2021;61(6):2596–2602.
   Web of Science ®Google Scholar
• Strand V, Gossec L, Proudfoot CWJ, et al. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus Adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):1.
   PubMedGoogle Scholar
• Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator Abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807–2816.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator Abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008;67(4):547–554.
   PubMed Web of Science ®Google Scholar
• Strand V, Balbir-Gurman A, Pavelka K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford). 2006;45(12):1505–1513.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J Rheumatol. 2008;35:1.
   Web of Science ®Google Scholar
• Strand V, Lee EB, Fleischmann R, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016;2(2):1–11.
   Google Scholar
• Strand V, van der Heijde D, Tanaka Y, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month phase 3 ORAL scan study. Clin Exp Rheumatol. 2020;38(5):848–857.
   PubMed Web of Science ®Google Scholar
• Strand V, Kremer JM, Gruben D, et al. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial. Arthritis Care Res. 2017;69(4):592–598.
   Web of Science ®Google Scholar
• Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther. 2015;17(1):1–12.
   PubMedGoogle Scholar
• Strand V, Tundia N, Wells A, et al. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from Select-Early And Select-Monotherapy. Rheumatol (United Kingdom). 2021;60(7):3209–3221.
   PubMed Web of Science ®Google Scholar
• Strand V, Pope J, Tundia N, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019;21(1):1–11.
   PubMed Web of Science ®Google Scholar
• Strand V, Schiff M, Tundia N, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2019;21(1):1–10.
   PubMed Web of Science ®Google Scholar
• Strand V, Tundia N, Bergman M, et al. Upadacitinib improves patient-reported outcomes vs placebo or Adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford). 2021;60(12):5583–5594.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Lee YC, Fleischmann R, et al. Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial. J Clin Med. 2019;8(6):6.
   Web of Science ®Google Scholar
• Fautrel B, Kirkham B, Pope JE, et al. Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM. J Clin Med. 2019;8(9):9.
   Web of Science ®Google Scholar
• Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506–517.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with Adalimumab plus methotrexate versus methotrexate alone or Adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Zhu B, Taylor PC, et al., Comparative effectiveness of improvement in pain and physical function for baricitinib versus Adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease. RMD Open. 2020;6(1):1–10.
   Web of Science ®Google Scholar
• Taylor PC, Alten R, Jmá G, et al. Original research: achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy. RMD Open. 2022;8(1):e001994.
   PubMed Web of Science ®Google Scholar
• Bingham CO, Walker D, Nash P, et al. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. Arthritis Res Ther. 2022;24(1):1–14.
   PubMedGoogle Scholar
• Genovese M, Westhovens R, Meuleners L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018;20(1):1–11.
   PubMedGoogle Scholar
• Ocampo VD, Gladman D. Psoriatic arthritis. F1000Res. 2019;8:1–16.
   Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510.
   PubMed Web of Science ®Google Scholar
• Wervers K, Vis M, Tchetveriko I, et al. Burden of psoriatic arthritis according to different definitions of disease activity: comparing minimal disease activity and the disease activity index for psoriatic arthritis. Arthritis Care Res. 2018;70(12):1764–1770.
   Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol (Hoboken, NJ). 2016;68(5):1060–1071.
   PubMed Web of Science ®Google Scholar
• Orbai AM, De Wit M, Mease PJ, et al. Updating the psoriatic arthritic core domain set: a report from thePsA workshop at OMERACT 2016. J Rheumatol. 2017;44(10):1522.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Biologic therapy for psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):723–738.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Willian MK, Menter A, et al. Impact of Adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341–350.
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Alten R, Deodhar A, et al. Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD Open. 2020;6(2):2.
   Web of Science ®Google Scholar
• Rahman P, Zummer M, Bessette L, et al. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry. BMJ Open. 2017;7(8):2–9.
   Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Schett G, et al. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res Ther. 2018; 20(1). DOI:10.1186/s13075-018-1610-3.
   Google Scholar
• Poddubnyy D, Pournara E, Zielińska A, et al. Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. Ther Adv Musculoskelet Dis. 2021;13:1759720X211051471.
   PubMed Web of Science ®Google Scholar
• Augustin M, Lambert J, Zema C, et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. 2020;156(12):1.
   PubMed Web of Science ®Google Scholar
• Strand V, De Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL beyond. RMD Open. 2019;5(1).
   Web of Science ®Google Scholar
• Strand V, Mease PJ, Soriano ER, et al. Tofacitinib or adalimumab versus placebo: Patient-reported outcomes from OPAL Broaden - A phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open 2019;5(1):1–12.
   Web of Science ®Google Scholar
• Mease PJ, Lertratanakul A, Papp KA, et al. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study. Rheumatol Ther. 2021;8(2):903.
   PubMed Web of Science ®Google Scholar
• Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum. 2002;47(4):391–397.
   PubMedGoogle Scholar
• Freynhagen R, Parada HA, Calderon-Ospina CA, et al., Current understanding of the pain concept: a brief narrative review. Curr Med Res Opin. 2019;35(6):1011–1018.
   PubMed Web of Science ®Google Scholar
• Duffield SJ, Miller N, Zhao S, et al. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(8):1453–1460.
   PubMed Web of Science ®Google Scholar
• Shraim MA, Massé-Alarie H, Hodges PW. Methods to discriminate between mechanism-based categories of pain experienced in the musculoskeletal system: a systematic review. Pain. 2021;162(4):1007–1037.
   PubMed Web of Science ®Google Scholar
• Leroux A, Rzasa-Lynn R, Crainiceanu C, et al. Wearable devices: current status and opportunities in pain assessment and management. Digit Biomark. 2021;5(1):89–102
   PubMedGoogle Scholar
• Rathbun AM, Harrold LR, Reed GW. Temporal effect of depressive symptoms on the longitudinal evolution of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 2015;67(6):765–775.
   PubMed Web of Science ®Google Scholar
• Leblanc-Trudeau C, Dobkin PL, Carrier N, et al. Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis. Rheumatology (Oxford). 2015;54(12):2205–2214.
   PubMed Web of Science ®Google Scholar
• Hammer HB, Uhlig T, Kvien TK, et al. Pain catastrophizing, subjective outcomes, and inflammatory assessments including ultrasound: results from a longitudinal study of rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2018;70(5):703–712.
   PubMed Web of Science ®Google Scholar
• Salaffi F, Carotti M, Farah S, et al. Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis. Inflammopharmacology. 2022;30(3):1119–1128.
   PubMed Web of Science ®Google Scholar
• Miyagawa I, Tanaka Y. Dawn of precision medicine in psoriatic arthritis. Front Med (Lausanne). 2022;9:851892.
   PubMed Web of Science ®Google Scholar
• Miyagawa I, Nakayamada S, Nakano K, et al. Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (Oxford). 2019;58(2):336–344.
   PubMed Web of Science ®Google Scholar
• Hosseinikhah SM, Barani M, Rahdar A, et al. Nanomaterials for the diagnosis and treatment of inflammatory arthritis. Int J Mol Sci. 2021;22(6):3092.
   PubMed Web of Science ®Google Scholar